Bactiguard and Zimmer Biomet agreed to expand a global license partnership, initiated in 2019, to cover multiple product segments.
The extended exclusive license agreement covers implants for hip and knee joint reconstruction, sports medicine, craniomaxillofacial and thoracic applications. It includes license and development fees of $1.5 million payable in 2022, additional contingent milestone payments of $7.5 million based on U.S. regulatory clearance for different product categories, and royalties on net sales following commercialization.
The agreement does not cover dental and spine applications that will be spun off by Zimmer Biomet to ZimVie.
In 2019, Bactiguard and Zimmer Biomet partnered to develop orthopedic trauma implants with Bactiguard’s technology to prevent post-op infections. European regulatory clearance was obtained in 2021, based on Bactiguard’s Orthosyn trauma implant. Zimmer Natural Nail (ZNN) Bactiguard implants were launched in Europe and other select markets in 2Q21. The registration process in the U.S. and other major markets is ongoing.
“Our partnership with Zimmer Biomet has developed in a very positive way over the past two and a half years. Less than two years from the start, we were able to launch ZNN Bactiguard trauma implants in Europe, and we have now agreed to expand the scope across Zimmer Biomet’s product range. This is a major step forward and clearly positions the Bactiguard technology in the orthopedic space, which has been a top priority for us,” said Anders Göransson, Bactiguard CEO.
Bactiguard and Zimmer Biomet agreed to expand a global license partnership, initiated in 2019, to cover multiple product segments.
The extended exclusive license agreement covers implants for hip and knee joint reconstruction, sports medicine, craniomaxillofacial and thoracic applications. It includes license and development fees of $1.5 million...
Bactiguard and Zimmer Biomet agreed to expand a global license partnership, initiated in 2019, to cover multiple product segments.
The extended exclusive license agreement covers implants for hip and knee joint reconstruction, sports medicine, craniomaxillofacial and thoracic applications. It includes license and development fees of $1.5 million payable in 2022, additional contingent milestone payments of $7.5 million based on U.S. regulatory clearance for different product categories, and royalties on net sales following commercialization.
The agreement does not cover dental and spine applications that will be spun off by Zimmer Biomet to ZimVie.
In 2019, Bactiguard and Zimmer Biomet partnered to develop orthopedic trauma implants with Bactiguard’s technology to prevent post-op infections. European regulatory clearance was obtained in 2021, based on Bactiguard’s Orthosyn trauma implant. Zimmer Natural Nail (ZNN) Bactiguard implants were launched in Europe and other select markets in 2Q21. The registration process in the U.S. and other major markets is ongoing.
“Our partnership with Zimmer Biomet has developed in a very positive way over the past two and a half years. Less than two years from the start, we were able to launch ZNN Bactiguard trauma implants in Europe, and we have now agreed to expand the scope across Zimmer Biomet’s product range. This is a major step forward and clearly positions the Bactiguard technology in the orthopedic space, which has been a top priority for us,” said Anders Göransson, Bactiguard CEO.
Copy to clipboard 
